findmyKOL
Clinical trialNCT00004029CompletedPhase 1Interventional

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

SponsorNational Cancer Institute (NCI)Enrollment46Prostate Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Phase I trial to study the effectiveness of vaccine therapy in treating patients with metastatic prostate cancer. Vaccines may make the body build an immune response to kill tumor cells.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Brigham and Women'S Hospital

    Boston, Massachusetts, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Recombinant viral vaccine therapySargramostim →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Dec 1996
Primary completion
31 May 2006
Completion
—
Last update posted
11 Feb 2013
Registered enrollment
46
Registry id
NCT00004029

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.